BDSI Key Statistics, Chart & Performance
The current stock price of BDSI is 5.59 null. In the past month the price increased by 0.72%. In the past year, price increased by 53.15%.
BDSI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BDSI. When comparing the yearly performance of all stocks, BDSI is one of the better performing stocks in the market, outperforming 97.69% of all stocks.
BDSI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BDSI. While BDSI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
BDSI Financial Highlights
Over the last trailing twelve months BDSI reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 232% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 50.91% | ||
| ROA | 26.14% | ||
| ROE | 45.18% | ||
| Debt/Equity | 0.29 |
BDSI Forecast & Estimates
13 analysts have analysed BDSI and the average price target is 5.48 null. This implies a price decrease of -1.88% is expected in the next year compared to the current price of 5.59.
For the next year, analysts expect an EPS growth of -57.48% and a revenue growth 22.27% for BDSI
BDSI Ownership
BDSI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 1T | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 578.208B | ||
| MRK | MERCK & CO. INC. | 22.54 | 302.633B | ||
| PFE | PFIZER INC | 9.06 | 154.765B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 126.196B | ||
| ZTS | ZOETIS INC | 18.55 | 56.153B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.774B | ||
| VTRS | VIATRIS INC | 5.76 | 16.793B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 222.91 | 9.202B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BDSI
Company Profile
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
Company Info
BIODELIVERY SCIENCES INTL
4131 Parklake Ave Ste 225
Raleigh NORTH CAROLINA 27612 US
CEO: Jeffrey Bailey
Employees: 200
Phone: 19195829050.0
BIODELIVERY SCIENCES INTL / BDSI FAQ
What does BIODELIVERY SCIENCES INTL do?
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
Can you provide the latest stock price for BIODELIVERY SCIENCES INTL?
The current stock price of BDSI is 5.59 null. The price decreased by -0.09% in the last trading session.
Does BDSI stock pay dividends?
BDSI does not pay a dividend.
What is the ChartMill rating of BIODELIVERY SCIENCES INTL stock?
BDSI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in BIODELIVERY SCIENCES INTL be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BDSI.
What is BIODELIVERY SCIENCES INTL worth?
BIODELIVERY SCIENCES INTL (BDSI) has a market capitalization of 552.29M null. This makes BDSI a Small Cap stock.